Structure and function of dopamine receptors

Neuroscience and Biobehavioral Reviews

Volumn 24, Issue 1, 2000, Pages 125-132

  Vallone, Daniela ^a   Picetti, Roberto ^a   Borrelli, Emiliana ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Dopamine; Dopamine receptors; Knock out mice; Neuronal disease

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BROMOCRIPTINE; BUTACLAMOL; CHLORPROMAZINE; CLOZAPINE; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROTRANSMITTER; PROPYLNORAPOMORPHINE; QUINPIROLE; RACLOPRIDE; RECEPTOR SUBTYPE; REMOXIPRIDE; RISPERIDONE; SPIPERONE; SULPIRIDE;

ANIMAL MODEL; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; BRAIN INJURY; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPOPHYSIS TUMOR; KNOCKOUT MOUSE; LOCOMOTION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINE; HUMANS; PROTEIN CONFORMATION; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION;

EID: 0033957873     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(99)00063-9     Document Type: Conference Paper

References (87)

1. Feldman R.S., Meyer J.S., Quenzer L.F. Catecholamines. Principles of neuropsychopharmacology. 1997;Sinauer Associates, Inc, Sunderland, MA. p. 277-344.
2. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci. 15:1992;285-320.
3. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med. 339:1998;1044-1053.
4. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med. 339:1998;1130-1143.
5. Le Moal M., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev. 71:1991;155-234.
6. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 13:1992;177-184.
7. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
8. Doppler W. Regulation of gene expression by prolactin. Rev Physiol Biochem Pharmacol. 124:1994;93-130.
9. Saiardi A., Bozzi Y., Baik J.H., Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron. 19:1997;115-126.
10. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 16:1993;299-321.
11. Bates M.D., Senogles S.E., Bunzow J.R., Liggett S.B., Civelli O., Caron M.G. Regulation of responsiveness at D2 dopamine receptors by receptor desensitization and adenylyl cyclase sensitization. Mol Pharmacol. 39:1991;55-63.
12. Journot L., Homburger V., Pantaloni C., Priam M., Bockaert J., Enjalbert A. An islet activating protein-sensitive G protein is involved in dopamine inhibition of angiotensin and thyrotropin-releasing hormone-stimulated inositol phosphate production in anterior pituitary cells. J Biol Chem. 262:1987;15 106-15 110.
13. Ng G.Y., Mouillac B., George S.R., Caron M., Dennis M., Bouvier M., O'Dowd B.F. Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. Eur J Pharmacol. 267:1994;7-19.
14. Bunzow J.R., Van Tol H.H., Grandy D.K., Albert P., Salon J., Christie M., Machida C.A., Neve K.A., Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA [see comments]. Nature. 336:1988;783-787.
15. Chio C.L., Hess G.F., Graham R.S., Huff R.M. A second molecular form of D2 dopamine receptor in rat and bovine caudate nucleus. Nature. 343:1990;266-269.
16. Dal Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A., Shivers B.D., Seeburg P. II. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 8:1989;4025-4034.
17. Giros B., Sokoloff P., Martres M.P., Riou J.F., Emorine L.J., Schwartz J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 342:1989;923-926.
18. Martens G.J., Molhuizen H.O., Groneveld D., Roubos E.W. Cloning and sequence analysis of brain cDNA encoding a Xenopus D2 dopamine receptor. FEBS Lett. 281:1991;85-89.
19. Montmayeur J.P., Bausero P., Amlaiky N., Maroteaux L., Hen R., Borrelli E. Differential expression of the mouse D2 dopamine receptor isoforms. FEBS Lett. 278:1991;239-243.
20. Jackson D.M., Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther. 64:1994;291-370.
21. Kukstas L.A., Domec C., Bascles L., Bonnet J., Verrier D., Israel J.M., Vincent J.D. Different expression of the two dopaminergic D2 receptors, D2415 and D2444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 129:1991;1101-1103.
22. Grima B., Lamouroux A., Blanot F., Biguet N.F., Mallet J. Complete coding sequence of rat tyrosine hydroxylase mRNA. Proc Natl Acad Sci USA. 82:1985;617-621.
23. Fishburn C.S., Belleli D., David C., Carmon S., Fuchs S. A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J Biol Chem. 268:1993;5872-5878.
24. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
25. Beischlag T.V., Marchese A., Meador-Woodruff J.H., Damask S.P., O'Dowd B.F., Tyndale R.F., Van Tol H.H., Seeman P., Niznik H.B. The human dopamine D5 receptor gene: cloning and characterization of the 5′-flanking and promoter region. Biochemistry. 34:1995;5960-5970.
26. Kamakura S., Iwaki A., Matsumoto M., Fukumaki Y. Cloning and characterization of the 5′-flanking region of the human dopamine D4 receptor gene. Biochem Biophys Res Commun. 235:1997;321-326.
27. Minowa M.T., Minowa T., Monsma F.J. Jr., Sibley D.R., Mouradian M.M. Characterization of the 5( flanking region of the human D1A dopamine receptor gene. Proc Natl Acad Sci USA. 89:1992;3045-3049. published erratum appears in Proc Natl Acad Sci USA 1992;89(9):4220.
28. Valdenaire O., Vernier P., Maus M., Dumas Milne Edwards J.B., Mallet J. Transcription of the rat dopamine-D2-receptor gene from two promoters. Eur J Biochem. 220:1994;577-584.
29. Chernak J.M., Hoffman P.W., Minowa T., Mouradian M.M., Roth G.S. Interaction of nuclear factors from young and old rat brain regions with regulatory sequences of the D2 dopamine receptor gene promoter. Brain Res Mol Brain Res. 4:1997;113-124.
30. Samad T.A., Krezel W., Chambon P., Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci USA. 94:1997;14 349-14 354.
31. Krezel W., Ghyselinck N., Samad T.A., Dupe V., Kastner P., Borrelli E., Chambon P. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science. 279:1998;863-867.
32. Civelli O., Bunzow J.R., Grandy D.K., Zhou Q.Y., Van Tol H.H. Molecular biology of the dopamine receptors. Eur J Pharmacol. 207:1991;277-286.
33. Picetti R., Saiardi A., Abdel Samad T, Bozzi Y., Baik J.H., Borrelli E. Dopamine D2 receptors in signal transduction and behavior. Crit Rev Neurobiol. 11:1997;121-142.
34. Hepler J.R., Gilman A.G. G proteins. Trends Biochem Sci. 17:1992;383-387.
35. Strader C.D., Sigal I.S., Dixon R.A. Structural basis of beta-adrenergic receptor function. FASEB J. 3:1989;1825-1832.
36. Guiramand J., Montmayeur J.P., Ceraline J., Bhatia M., Borrelli E. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem. 270:1995;7354-7358.
37. Montmayeur J.P., Guiramand J., Borrelli E. Preferential coupling between dopamine D2 receptors and G-proteins. Mol Endocrinol. 7:1993;161-170.
38. Liu Y.F., Jakobs K.H., Rasenick M.M., Albert P.R. G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells. J Biol Chem. 269:1994;13 880-13 886.
39. Monsma F.J. Jr., Mahan L.C., McVittie L.D., Gerfen C.R., Sibley D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci USA. 87:1990;6723-6727.
40. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H., Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 350:1991;614-619.
41. Choi E.J., Xia Z., Villacres E.C., Storm D.R. The regulatory diversity of the mammalian adenylyl cyclases. Curr Opin Cell Biol. 5:1993;269-273.
42. Hofmann F., Biel M., Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci. 17:1994;399-418.
43. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev. 78:1998;189-225.
44. Robinson S.W., Caron M.G. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol Pharmacol. 52:1997;508-514.
45. 2+ current by the dopamine D1 receptor in rat adrenal glomerulosa cells: requirement of the combined action of the G betagamma protein subunit and cyclic adenosine 3′,5′-monophosphate. Mol Endocrinol. 11:1997;503-514.
46. Yan Z., Song W.J., Surmeier J. D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J Neurophysiol. 77:1997;1003-1015.
47. Taraskevich P.S., Douglas W.W. Dopamine (D2) or gamma-aminobutyric acid (GABAB) receptor activation hyperpolarizes rat melanotrophs and pertussis toxin blocks these responses and the accompanying fall in [Ca2+]i. Neurosci Lett. 112:1990;205-209.
48. Braun A.P., Schulman H. The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. Annu Rev Physiol. 57:1995;417-445.
49. Liu L.X., Monsma F.J. Jr., Sibley D.R., Chiodo L.A. D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse. 24:1996;156-164.
50. Piomelli D. Arachidonic acid in cell signaling. Curr Opin Cell Biol. 5:1993;274-280.
51. Meyer M.E., Van Hartesveldt C., Potter T.J. Locomotor activity following intra-accumbens microinjections of dopamine D1 agonist SK&F 38393 in rats. Synapse. 13:1993;310-314.
52. Meyer M.E., Cottrell G.A., Van Hartesveldt C., Potter T.J. Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol Biochem Behav. 44:1993;429-432.
53. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg A., Lee E.J., Huang S.P., Bartlett P.F., Jose P.A., Sibley D.R., Westphal H. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc Natl Acad Sci USA. 91:1994;12564-12568.
54. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 79:1994;729-742.
55. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., Le Meur M., Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 377:1995;424-428.
56. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA. 93:1996;1945-1949.
57. Rubinstein M., Phillips T.J., Bunzow J.R., Falzone T.L., Dziewezapolski G., Zhang G., Fang Y., Larson J.L., McDougall J.A. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 90:1997;991-1001.
58. Svensson K., Carlsson A., Huff R.M., Kling-Petersen T., Waters N. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol. 263:1994;235-243.
59. Gingerich K.J., Turnock P., Litfin J.K., Rosen J. Diversity and attention deficit hyperactivity disorder. J Clin Psychol. 54:1998;415-426.
60. Amara S.G., Kuhar M.J. Neurotransmitter transporters: recent progress. Annu Rev Neurosci. 16:1993;73-93.
61. Sora I., Wichems C., Takahashi N., Li X.F., Zeng Z., Lesch K.P., Murphy D.L., Uhl G.R. Cocaine reward models conditioned place preference can be established in dopamine-and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA. 95:1998;7699-7704.
62. Cook E.H. Jr, Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 56:1995;993-998.
63. Gill M., Daly G., Heron S., Hawi Z., Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiat. 2:1997;311-313.
64. La Hoste G.J., Swanson J.M., Wigal S.B., Glabe C., Wigal T., King N., Kennedy J.L. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder [see comments]. Mol Psychiatry. 1:1996;121-124.
65. Swanson J.M., Sunohara G.A., Kennedy J.L., Regino R., Fineberg E., Wigal T., Lerner M., Williams L., La Hoste G.J., Wigal S. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol Psychiatry. 3:1998;38-41.
66. Carey M.P., Diewald L.M., Esposito F.J., Pellicano M.P., Gironi Carnevale U.A., Sergeant J.A., Papa M., Sadile A.G. Differential distribution, affinity and plasticity of dopamine D-1 and D-2 receptors in the target sites of the mesolimbic system in an animal model of ADHD. Behav Brain Res. 94:1998;173-185.
67. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 283:1999;397-401.
68. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
69. Shuster L., Hudson J., Anton M., Righi D. Sensitization of mice to methylphenidate. Psychopharmacology (Berl). 77:1982;31-36.
70. Woolverton W.L., Johonson K.M. Neurobiology of cocaine abuse. Trends Pharmacol Sci. 13:1999;193-200.
71. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev. 94:1987;469-492.
72. Wise R.A. Neurobiology of addiction. Curr Opin Neurobiol. 6:1996;243-251.
73. Callahan P.M., De la Garza R., Cunningham K.A. Discriminative stimulus properties of cocaine: modulation by dopamine D1 receptors in the nucleus accumbens. Psychopharmacology (Berl). 115:1994;110-114.
74. Drago J., Gerfen C.R., Westphal H., Steiner H. D1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience. 74:1996;813-823.
75. Miner L.L., Drago J., Chamberlain P.M., Donovan D., Uhl G.R. Retained cocaine conditioned place preference in D1 receptor deficient mice. Neuroreport. 6:1995;2314-2316.
76. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 388:1997;586-589.
77. Konradi C., Cole R.L., Heckers S., Hyman S.E. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci. 14:1994;5623-5634.
78. Cole A.J., Bhat R.V., Patt C., Worley P.F., Baraban J.M. D1 dopamine receptor activation of multiple transcription factor genes in rat striatum. J Neurochem. 58:1992;1420-1426.
79. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA. 87:1990;6912-6916.
80. Hope B., Kosofsky B., Hyman S.E., Nestler E.J. Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc Natl Acad Sci USA. 89:1992;5764-5768.
81. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA. 89:1992;4270-4274.
82. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci. 18:1995;463-495.
83. Young S.T., Porrino L.J., Iadarola M.J. Cocaine induces striatal c-fos-immunoreactive proteins via dopaminergic D1 receptors. Proc Natl Acad Sci USA. 88:1991;1291-1295.
84. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci. 14:1991;421-451.
85. Sonnenberg J.L., Rauscher F.J., Morgan J.I., Curran T. Regulation of proenkephalin by Fos and Jun. Science. 246:1989;1622-1625.
86. Draisci G., Iadarola M.J. Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. Brain Res Mol Brain Res. 6:1989;31-37.
87. Ruskin D.N., Marshall J.F. Amphetamine- and cocaine-induced fos in the rat striatum depends on D2 dopamine receptor activation. Synapse. 18:1994;233-240.